PRISMAP
Financiado
The European medical isotope programme Production of high purity isotopes by ma...
The European medical isotope programme Production of high purity isotopes by mass separation
PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of the key European intense neutron sources, isotope mass separation facilities and high-pow...
PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of the key European intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment. PRISMAP will create a single-entry point for a fragmented user community distributed amongst universities, research centres, industry and hospitals, in a similar way as the National Isotope Development Center NIDC supported by the Department of Energy (DOE) has provided radionuclide sources for users in the USA. PRISMAP brings together a consortium of 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation. It further receives support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA). Our main goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardised access procedures. The new isotope enrichment and standardisation techniques triggered in PRISMAP will expand our services and provide them to yet unreachable remote European laboratories. PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer – one of the major diseases in Europe - theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of a better healthcare for the improvement of our citizens’ life.
ver más
Duración del proyecto: 45 meses
Fecha Inicio: 2021-07-07
Fecha Fin: 2025-04-30
Fecha Fin: 2025-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-07-07
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
INFRAIA-02-2020:
Integrating Activities for Starting Communities
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
6M€
Líder del proyecto
International Committee of the Red Cross
No se ha especificado una descripción o un objeto social para esta compañía.
1.11M€ |
Participante
74.33K€ |
Participante
343.50K€ |
Participante